Oxaliplatin With S-1 （SOX）
Phase 2Small molecule
Oxaliplatin With S-1 （SOX） is one of 15 small molecule programs targeting Gastric Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Perjeta
RochePhase 3
Bemarituzumab
AmgenPhase 3
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Oxaliplatin With S-1 （SOX）
SSixth Affiliated Hospital, Sun Yat-sen University
Phase 2
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxaliplatin With S-1 （SOX）. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details